Moderna raises its revenue outlook — but all eyes are on what happens next with its experimental cancer vaccine
The company lifted its revenue outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
The company lifted its revenue outlook for the year, saying it expects revenue to grow as much as 25% in 2026. This story matters for Finance & Markets readers tracking largecap. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. LargecapNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily largecap signal